Clinical trial
Establishment of Post-Operative Optimal Surveillance Model and Adaptive Treatment Decision System Based on MRD Molecular Response Combined With Pathological Response Status
NCT07894458 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Establishment of Post-Operative Optimal Surveillance Model and Adaptive Treatment Decision System Based on MRD Molecular Response Combined With Pathological Response Status
- Lead sponsor
- Peking University People's Hospital
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- August 12, 2026
- Completion date
- October 31, 2027
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
immunotherapy, lung neoplasms, minimal residual disease, neoadjuvant therapy
Arms
As registered; 1 arm.
-
MRD-Guided Adaptive Postoperative Management Group
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Two-year recurrence-free survival rate
Lead sponsor's other trials
Peking University People's Hospital, most recent start first.
+604 more trials See the organization page
Similar trials
Same condition (Neoplasm, Residual) and phase, most recent start first.
+30 more trials See the condition page